Vertex Pharma (VRTX) Tops Q2 EPS by 3c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Jefferies Raises Price Target on Vertex Pharma (VRTX) to $107; Reiterates Buy
July 28, 2016 9:07 AM EDTJefferies reiterated a Buy rating on Vertex Pharma (NASDAQ: VRTX), and raised the price target to $107.00 (from $102.00), following the company's 2Q earnings report. Orkambi sales fell slightly short of $249M estimates. Vertex continues to expect persistence and compliance rates on... More
